Immunotherapies for hepatocellular carcinoma
JM Llovet, F Castet, M Heikenwalder… - Nature reviews Clinical …, 2022 - nature.com
Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …
cause of cancer-related death and its incidence is increasing globally. Around 50% of …
The immunological and metabolic landscape in primary and metastatic liver cancer
X Li, P Ramadori, D Pfister, M Seehawer… - Nature Reviews …, 2021 - nature.com
The liver is the sixth most common site of primary cancer in humans, and generally arises in
a background of cirrhosis and inflammation. Moreover, the liver is frequently colonized by …
a background of cirrhosis and inflammation. Moreover, the liver is frequently colonized by …
Advances in immunotherapy for hepatocellular carcinoma
B Sangro, P Sarobe, S Hervás-Stubbs… - Nature reviews …, 2021 - nature.com
Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …
[HTML][HTML] Hepatocellular carcinoma
Liver cancer remains a global health challenge, with an estimated incidence of> 1 million
cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer …
cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer …
[PDF][PDF] Emerging immunotherapy for HCC: A guide for hepatologists
HCC is one of the most common cancers worldwide, and the third leading cause of cancer‐
related death globally. HCC comprises nearly 90% of all cases of primary liver cancer …
related death globally. HCC comprises nearly 90% of all cases of primary liver cancer …
T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis via integrating single-cell RNA-seq and bulk RNA-sequencing
H Chi, S Zhao, J Yang, X Gao, G Peng… - Frontiers in …, 2023 - frontiersin.org
Background Hepatocellular carcinoma (HCC), the third most prevalent cause of cancer-
related death, is a frequent primary liver cancer with a high rate of morbidity and mortality. T …
related death, is a frequent primary liver cancer with a high rate of morbidity and mortality. T …
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Y Simoni, E Becht, M Fehlings, CY Loh, SL Koo… - Nature, 2018 - nature.com
Various forms of immunotherapy, such as checkpoint blockade immunotherapy, are proving
to be effective at restoring T cell-mediated immune responses that can lead to marked and …
to be effective at restoring T cell-mediated immune responses that can lead to marked and …
The immunology of hepatocellular carcinoma
M Ringelhan, D Pfister, T O'Connor, E Pikarsky… - Nature …, 2018 - nature.com
In contrast to most other malignancies, hepatocellular carcinoma (HCC), which accounts for
approximately 90% of primary liver cancers, arises almost exclusively in the setting of …
approximately 90% of primary liver cancers, arises almost exclusively in the setting of …
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Background For patients with advanced hepatocellular carcinoma, sorafenib is the only
approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and …
approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and …
From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma
Y Fu, S Liu, S Zeng, H Shen - Journal of Experimental & Clinical Cancer …, 2019 - Springer
Hepatocellular carcinoma (HCC) ranks the most common primary liver malignancy and the
third leading cause of tumor-related mortality worldwide. Unfortunately, despite advances in …
third leading cause of tumor-related mortality worldwide. Unfortunately, despite advances in …